Actinium Pharmaceuticals, Inc. (ATNM) |
6.85 0.18 (2.7%) 04-19 16:00 |
Open: | 6.64 |
High: | 7.01 |
Low: | 6.6 |
Volume: | 342,640 |
Market Cap: | 201(M) |
PE Ratio: | -3.74 |
Exchange: | American Stock Exchange |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 9.86 |
Resistance 1: | 8.45 |
Pivot price: | 8.45 |
Support 1: | 6.16 |
Support 2: | 5.13 |
52w High: | 9.86 |
52w Low: | 4 |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
EPS | -1.930 |
Book Value | 1.590 |
PEG Ratio | 0.00 |
Gross Profit | 0.038 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -32.1 |
Return on Equity (ttm) | -87.3 |
Fri, 19 Apr 2024
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty - Barchart
Thu, 18 Apr 2024
The Globe and Mail - The Globe and Mail
Thu, 18 Apr 2024
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM) - Barchart
Wed, 17 Apr 2024
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid ... - WICZ
Tue, 19 Mar 2024
Should You Buy Actinium Pharmaceuticals Inc (ATNM) Stock Tuesday Morning? - InvestorsObserver
Mon, 11 Mar 2024
Can Actinium Pharmaceuticals Inc (ATNM) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |